Cochrane · systematic review · CD012334
Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis
Zacharias, HD, Zacharias, AP, Gluud, LL, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
Hepato-BiliaryAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
11
current version
GRADE rated
9
No studies
2
Included studies
NR
No studies 2 · 18.2%Ungraded 0 · 0%Very low 9 · 81.8%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Phamacotherapies that specifically target ammonia versus placebo or non‐absorbable disaccharides for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis
Population: adults with cirrhosis and hepatic encephalopathy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Phamacotherapies that specifically target ammonia vs placebo or non‐absorbable disaccharides | no estimate extracted | 1 study · 16 participants | Very low Downgraded: risk of bias |
Hepatic encephalopathy Phamacotherapies that specifically target ammonia vs placebo or non‐absorbable disaccharides | no estimate extracted | NR | No studies |
Serious adverse events Phamacotherapies that specifically target ammonia vs placebo or non‐absorbable disaccharides | no estimate extracted | 1 study · 16 participants | Very low Downgraded: risk of bias |
Non‐serious adverse events Phamacotherapies that specifically target ammonia vs placebo or non‐absorbable disaccharides | no estimate extracted | 1 study · 16 participants | Very low Downgraded: risk of bias |
Health‐related quality of life Phamacotherapies that specifically target ammonia vs placebo or non‐absorbable disaccharides | no estimate extracted | NR | No studies |
Blood ammonia concentrations (µg/dL) Phamacotherapies that specifically target ammonia vs placebo or non‐absorbable disaccharides | no estimate extracted | 1 study · 16 participants | Very low Downgraded: risk of bias |
Blood ammonia concentrations Phamacotherapies that specifically target ammonia vs placebo or non‐absorbable disaccharides | no estimate extracted | 2 studies · 85 participants | Very low Downgraded: risk of bias |
Blood ammonia concentrations (µmol/L*week) Phamacotherapies that specifically target ammonia vs placebo or non‐absorbable disaccharides | no estimate extracted | 1 study · 178 participants | Very low Downgraded: risk of bias |
Blood ammonia concentrations (µmol/L) Phamacotherapies that specifically target ammonia vs placebo or non‐absorbable disaccharides | no estimate extracted | 1 study · 231 participants | Very low Downgraded: risk of bias |
Blood ammonia concentrations (units unspecified) Phamacotherapies that specifically target ammonia vs placebo or non‐absorbable disaccharides | no estimate extracted | 1 study · 35 participants | Very low Downgraded: risk of bias |
Blood ammonia levels (µmol/L) Phamacotherapies that specifically target ammonia vs placebo or non‐absorbable disaccharides | no estimate extracted | 2 studies · 90 participants | Very low Downgraded: risk of bias |